Cargando…

High‐dose IVIG plus cangrelor platelet “anesthesia” during urgent heparin‐CPB in a patient with recent SRA‐negative HIT‐thrombosis with persisting platelet‐activating antibodies

In a high‐risk patient with subacute heparin‐induced thrombocytopenia (HIT) type A (platelet count recovery following acute HIT but with persisting platelet‐activating antibodies), in whom urgent cardiac surgery was required, a key clinical question arose: could intraoperative heparin be given safel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koster, Andreas, Nazy, Ishac, Birschmann, Ingvild E., Smith, James W., Sheppard, Jo‐Ann I., Warkentin, Theodore E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443421/ https://www.ncbi.nlm.nih.gov/pubmed/32864557 http://dx.doi.org/10.1002/rth2.12348

Ejemplares similares

Combination of two complementary automated rapid assays for diagnosis of heparin‐induced thrombocytopenia (HIT)
por: Warkentin, Theodore E., et al.
Publicado: (2020)

Timeline of heparin‐induced thrombocytopenia seroconversion in serial plasma samples tested using an automated latex immunoturbidimetric assay
por: Warkentin, Theodore E., et al.
Publicado: (2019)

The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19
por: Jevtic, Stefan D., et al.
Publicado: (2022)

Platelet variability index: a measure of platelet count fluctuations in patients with immune thrombocytopenia
por: Li, Na, et al.
Publicado: (2021)

Pulmonary Embolism (PE) in Transit in Heparin-Induced Thrombocytopenia (HIT) With Negative Serotonin-Release Assay (SRA)
por: Cheema, Tayyab, et al.
Publicado: (2022)

Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Gabarin, Nadia, et al.
Publicado: (2022)

Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients
por: Prüller, Florian, et al.
Publicado: (2018)

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
por: Cavender, Matthew A., et al.
Publicado: (2016)

The use of cangrelor with heparin for left ventricular assist device implantation in a patient with acute heparin-induced thrombocytopenia
por: Gernhofer, Yan K., et al.
Publicado: (2018)

Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
por: Gabarin, Nadia, et al.
Publicado: (2021)

Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia
por: Giles, Jason B., et al.
Publicado: (2022)

Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
por: O’Donoghue, Michelle L., et al.
Publicado: (2016)

Urgent Revascularization of the Left Proximal Circumflex Following Cessation of Cangrelor Within Six Hours of Procedure
por: Huang, Sherri, et al.
Publicado: (2023)

Changes in the Proteome of Platelets from Patients with Critical Progression of COVID-19
por: Wolny, Monika, et al.
Publicado: (2023)

Cardioprotective Properties of the Platelet P2Y(12) Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood
por: Bell, R. M., et al.
Publicado: (2015)

SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia
por: Appelbaum, Jacob, et al.
Publicado: (2022)

Longitudinal Characteristics of Anti-Platelet Factor 4 Immunoglobulin G in Vaccine-Induced Immune Thrombotic Thrombocytopenia
por: Huynh, Angela, et al.
Publicado: (2022)

Autoimmune Heparin-Induced Thrombocytopenia
por: Warkentin, Theodore E.
Publicado: (2023)

High Platelet Reactivity after Transition from Cangrelor to Ticagrelor in Hypothermic Cardiac Arrest Survivors with ST-Segment Elevation Myocardial Infarction
por: Buchtele, Nina, et al.
Publicado: (2020)

COVID-19 versus HIT hypercoagulability
por: Warkentin, Theodore E., et al.
Publicado: (2020)

Cerebral venous sinus thrombosis associated with SRA-negative heparin-induced thrombocytopenia: case report
por: Silva, Floyd D., et al.
Publicado: (2023)

In vitro effect of an antithrombin in platelet activation by HIT antibodies
por: Eichler, P, et al.
Publicado: (2005)

Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder
por: Venier, Laura M., et al.
Publicado: (2022)

ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
por: Karnes, Jason H., et al.
Publicado: (2022)

Temporal presentations of heparin‐induced thrombocytopenia following cardiac surgery: A single‐center, retrospective cohort study
por: Warkentin, Theodore E., et al.
Publicado: (2022)

Challenges in Detecting Clinically Relevant Heparin-Induced Thrombocytopenia Antibodies
por: Warkentin, Theodore E.
Publicado: (2020)

Efficacy of Cangrelor as Bridging Therapy Post PCI
por: Khan, Abdul A., et al.
Publicado: (2020)

Correlation between preoperative platelet levels and heparin response
por: Ahmed, AB, et al.
Publicado: (1999)

Heparin Modulates the Endopeptidase Activity of Leishmania mexicana Cysteine Protease Cathepsin L-Like rCPB2.8
por: Judice, Wagner A. S., et al.
Publicado: (2013)

Heparin-induced thrombocytopenia
por: Jevtic, Stefan D., et al.
Publicado: (2021)

Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2016)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry
por: Selvarajah, Abi, et al.
Publicado: (2021)

The Appropriateness of Testing Platelet Factor 4/Heparin Antibody in Patients Suspected of Heparin-induced Thrombocytopenia
por: Jindal, Vishal, et al.
Publicado: (2018)

Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia
por: Tardy, Brigitte, et al.
Publicado: (2020)

Platelet phosphatidylserine is the critical mediator of thrombosis in heparin-induced thrombocytopenia
por: Zlamal, Jan, et al.
Publicado: (2023)

Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
por: De Luca, Leonardo, et al.
Publicado: (2021)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry
por: Selvarajah, A., et al.
Publicado: (2021)

The P2Y(12) Antagonists, 2MeSAMP and Cangrelor, Inhibit Platelet Activation through P2Y(12)/G(i)-Dependent Mechanism
por: Xiang, Binggang, et al.
Publicado: (2012)

Platelet Activation in Heparin-Induced Thrombocytopenia is Followed by Platelet Death via Complex Apoptotic and Non-Apoptotic Pathways
por: Mordakhanova, Elmira R., et al.
Publicado: (2020)

HIT-Heparin Induced Thrombocytopenia Simulation Case
por: Aouthmany, Shaza, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mhd6udj4haq5etgo8jin87t8ip